Creo Medical flags 60pc rise in first-quarter revenue.
Creo Medical said on Monday that first-quarter revenue rose about 60% year on year, at the upper end of management expectations, driven by customer adoption, higher procedure volumes and conversion of its commercial pipeline.
CREO MEDICAL GROUP
29 June 2026 14:16:18
Source: Sharecast
The AIM-traded medical device group now expects FY26 revenue growth of 50% to 60%, narrowed from previous guidance of 40% to 60%, and said recent updates on Speedboat, SpydrBlade Flex and MicroBlate Fine showed broader clinical and commercial traction.
Creo said it remained focused on efficiency after the sale and outsourcing of manufacturing, expected to cut annual operating costs by more than £1.0m, while a £5.5m placing and £2.0m convertible loan note subscription from the Development Bank of Wales would support inventory, customer roll-out and expansion.
At 1334 BST, shares in Creo Medical Group were up 8.89% at 14.7p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate
N/A
ISIN:
N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes
Compare our accounts
If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
